Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 3/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | PGAM1 | P18669 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158948 | 0.85 | AURKA (0.37) | GHSRBRD4JAK2LMNAHTR6 | |
| SCHEMBL14158573 | 0.78 | CYBB (0.42) | BRD4LMNAHTR6SLC40A1PGAM1 | |
| SCHEMBL14242806 | 0.78 | LMNA (0.43) | BRD4LMNAHTR6SLC40A1PGAM1 | |
| SCHEMBL14158776 | 0.77 | CYBB (0.45) | ABL1BCRJAK2PGAM1 | |
| SCHEMBL14243367 | 0.77 | CYBB (0.42) | LMNAHTR6SLC40A1PGAM1TP53 | |
| SCHEMBL14158760 | 0.77 | HTR6 (0.42) | GHSRLMNAHTR6SLC40A1PGAM1 | |
| SCHEMBL14242800 | 0.75 | LRRK2 (0.45) | LMNAHTR6PGAM1TP53THRB | |
| SCHEMBL14158821 | 0.74 | SLC40A1 (0.42) | GHSRLMNAHTR6SLC40A1PGAM1 | |
| SCHEMBL14158652 | 0.74 | PIK3CD (0.40) | LMNAHTR6SLC40A1PGAM1TP53 | |
| SCHEMBL14243380 | 0.74 | FLT3 (0.42) | BRD4JAK2LMNAHTR6BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | GHSR 4127/4885BRD4 998/4885ABL1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.